Form 4: Sangamo Officer's RSU Tax Withholding Reported

Sangamo Therapeutics' Principal Accounting Officer, Nikunj Jain, reported a disposition of 578 shares for mandatory tax withholding related to restricted stock unit vesting.

Summary

• Nikunj Jain, Principal Accounting Officer of Sangamo Therapeutics, Inc. (SGMO), reported a transaction on November 24, 2025.
• The transaction involved the disposition of 578 shares of common stock at a price of $0.4166 per share.
• This disposition was solely for mandatory tax withholding purposes upon the vesting of a portion of a restricted stock unit (RSU) grant.
• The shares were surrendered to the Issuer using the closing stock price on November 24, 2025, as per the company's Amended and Restated 2018 Equity Incentive Plan.
• This was not a discretionary trade by the Reporting Person.
• Following this transaction, Nikunj Jain beneficially owns 245,717 shares of common stock.
• The reported beneficial ownership includes 1,039 shares from the November 24, 2025 vesting installment of a February 24, 2023 RSU grant.
• It also includes 18,750 shares from a January 22, 2024 RSU grant and 49,726 shares from a February 25, 2025 RSU grant, subject to future vesting schedules.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction for tax withholding purposes related to RSU vesting, which is a neutral event and does not reflect positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

Future vesting schedules for Nikunj Jain's RSU grants include 1,618 shares vesting on February 24, 2026, 18,750 shares vesting in successive equal quarterly installments through January 22, 2026, and 49,726 shares vesting one-quarter on February 25, 2026, with the remainder in 8 successive equal quarterly installments thereafter. All vesting is contingent on continuous service.

Industry Context

This filing is a routine insider transaction report (Form 4) detailing a non-discretionary disposition of shares for tax withholding purposes upon RSU vesting. It does not provide broader industry context or competitive insights.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and not a sale reflecting management's view on the stock.

Next Steps

• Remaining 1,618 shares from the February 24, 2023 RSU grant will vest on February 24, 2026.
• 18,750 shares from the January 22, 2024 RSU grant will continue to vest in successive equal quarterly installments through January 22, 2026.
• 49,726 shares from the February 25, 2025 RSU grant will vest as to one-quarter (1/4) on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, RSU, Restricted Stock Unit, Tax Withholding, Equity Incentive Plan